CialisThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9

442 records returned

Physicochemical characterization of solid dispersion systems of tadalafil with poloxamer 407.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dissolution behaviour of a poorly water-soluble drug, tadalafil, from its solid dispersion systems with poloxamer 407 has been investigated. Solid dispersion systems of tadalafil were prepared with poloxamer 407 in 1:0.5, 1:1.5 and 1:2.5 ratios using the melting method. Characterization of binary systems with FTIR and XRPD studies demonstrated the presence of strong hydrogen bonding interactions, a significant decrease in crystallinity and the possibility of existence of amorphous entities of the drug. In the binary systems tested, 1:0.5 proportion of tadalafil/poloxamer 407 showed rapid dissolution of tadalafil (DE30 ...
Source: Acta Pharmaceutica - November 20, 2009 Category: Drugs & Pharmacology Authors: Vyas V, Sancheti P, Karekar P, Shah M, Pore Y Tags: Acta Pharm Source Type: journals

Phosphodiesterase Type 5 Inhibitors and Female Sexual Response: Faulty Protocols or Paradigms?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions. The lack of efficacy of PDE5 treatment in women is likely attributable to gender differences in the concordance between physiological and psychological components of sexual response. Discordance between genital and subjective measures of sexual response in women may be augmented by PDE5 effects on genital vasocongestion in some populations, rendering successful treatment unlikely via pharmacological treatment alone. Chivers M, and Rosen RC. PDE5 inhibitors and female sexual response: Faulty protocols or paradigms? J Sex Med **;**:**[ndash]**. (Source: The Journal of Sexual Medicine)
Source: The Journal of Sexual Medicine - November 19, 2009 Category: Sexual Medicine Authors: Meredith L. Chivers, Raymond C. Rosen Source Type: journals

Hair analysis to demonstrate administration of sildenafil to a woman in a case of drug-facilitated sexual assault. - Kintz P, Evans J, Villain M, Chatterton C, Cirimele V.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The drug sildenafil (Viagra, Pfizer) and, more recently, tadalafil (Cialis, Lilly-Icos) and vardenafil (Levitra, Bayer), has drawn public attention to aphrodisiacs. The search for such substances dates back millennia. Adverse effects associated with these ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - November 15, 2009 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: info

Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial HypertensionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A 46-year-old-woman presents with exertional dyspnea and syncope and receives a diagnosis of idiopathic pulmonary arterial hypertension. Treatment with sildenafil is recommended. Sildenafil and tadalafil are phosphodiesterase type 5 inhibitors that ameliorate pulmonary arterial hypertension by increasing levels of cyclic guanosine monophosphate in the smooth-muscle cells of the pulmonary artery. (Source: New England Journal of Medicine)
Source: New England Journal of Medicine - November 4, 2009 Category: Internal Medicine Authors: Archer, S. L., Michelakis, E. D. Tags: CLINICAL THERAPEUTICS Source Type: journals

Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion:Oral PDE-5 inhibitors improved erectile functioning and had similar efficacy and safety profiles. Results on the efficacy of hormonal treatments and the value of hormone testing in men with ED were inconclusive.Primary Funding Source:Agency for Healthcare Research and Quality. PMID: 19884626 [PubMed - as supplied by publisher] (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 3, 2009 Category: Internal Medicine Authors: Tsertsvadze A, Fink HA, Yazdi F, Macdonald R, Bella AJ, Ansari MT, Garritty C, Soares-Weiser K, Daniel R, Sampson M, Fox S, Moher D, Wilt TJ Tags: Ann Intern Med Source Type: journals

Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Description:The American College of Physicians developed this guideline to present the available evidence on hormonal testing in and pharmacologic management of erectile dysfunction. Current pharmacologic therapies include phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, vardenafil, tadalafil, mirodenafil, and udenafil, and hormonal treatment.Methods:Published literature on this topic was identified by using MEDLINE (1966 to May 2007), EMBASE (1980 to week 22 of 2007), Cochrane Central Register of Controlled Trials (second quarter of 2007), PsycINFO (1985 to June 2007), AMED (1985 to June 2007), and SCOPUS ...
Source: Annals of Internal Medicine - November 3, 2009 Category: Internal Medicine Authors: Qaseem A, Snow V, Denberg TD, Casey DE, Forciea MA, Owens DK, Shekelle P, Tags: Ann Intern Med Source Type: journals

Phosphodiesterase-5 inhibitors: future perspectives.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PDE-5 inhibitors were originally studied in cardiovascular indications but were later developed and approved for on-demand treatment of erectile dysfunction (ED). A few years ago sildenafil was approved for the treatment of pulmonary hypertension, thus renewing interest in cardiovascular applications, and tadalafil became available in once-daily formulations for erectile dysfunction management. Given the wide distribution of phosphodiesterase-5 throughout the body and its involvement in multiple functions, what can one expect in the future? To answer this we reviewed studies involving PDE-5 inhibitors that were publish...
Source: Current Pharmaceutical Design - October 29, 2009 Category: Drugs & Pharmacology Authors: Konstantinos G, Petros P Tags: Curr Pharm Des Source Type: journals

PDE5 Inhibitors in Non-Urological Conditions.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Phosphodiesterase type-5 (PDE5) inhibitors are widely used as first-line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an increasing understanding of cyclic guanosine monophosphate (cGMP)-regulated mechanisms, have triggered a number of attempts to determine their effects and potential benefits in non-urological conditions. In recent years, extensive and diverse preclinical and clinical evidence has been made available. PDE5 inhibition has shown collateral benefits for a multitude of risk factors or diseases associated with, or accompanying ED. To date, PDE5 inhibition has been shown to...
Source: Current Pharmaceutical Design - October 29, 2009 Category: Drugs & Pharmacology Authors: Vlachopoulos C, Terentes-Printzios D, Ioakeimidis N, Rokkas K, Stefanadis C Tags: Curr Pharm Des Source Type: journals

Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This article examines the peer-reviewed published data addressing patient's preference and adherence to ED treatment with PDE5 inhibitors. It also examines strategies to improve compliance and satisfaction with treatment. PMID: 19860694 [PubMed - in process] (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - October 29, 2009 Category: Drugs & Pharmacology Authors: Al-Shaiji TF, Brock GB Tags: Curr Pharm Des Source Type: journals

Phosphodiesterase type 5 inhibitors: unmet needs.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Erectile dysfunction (ED) has been revolutionized during the last two decades, as several treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety profiles. Despite the fact that more than 50 million ED patients have been treated successfully worldwide with PDE5i several issues remain to be addressed. Patients with severe neurologic damage, diabetes mellitus, or severe vascular disease may be resistant to PDE5i. Inappro...
Source: Current Pharmaceutical Design - October 29, 2009 Category: Drugs & Pharmacology Authors: Hatzimouratidis K, Hatzichristou DG Tags: Curr Pharm Des Source Type: journals

PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors - sildenafil (Viagra((R))), vardenafil (Levitra((R))) and tadalafil (Cialis((R))) - are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio((R))) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena((R))), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experiment...
Source: Current Pharmaceutical Design - October 29, 2009 Category: Drugs & Pharmacology Authors: Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C Tags: Curr Pharm Des Source Type: journals

Improvements in Confidence, Sexual Relationship and Satisfaction Measures: Results of a Randomized Trial of Tadalafil 5 mg Taken Once DailyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
How does tadalafil compare with placebo in treating erectile dysfunction? International Journal of Impotence Research (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - October 29, 2009 Category: Urology & Nephrology Tags: Urology Source Type: info

European CHMP supports change of indication for tadalafil (Adcirca®)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: EMEA Area: News The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, supporting the change of indication for tadalafil (Adcirca®) from erectile dysfunction (under name Tadalafil Lilly) to pulmonary arterial hypertension. (Source: NeLM - Urology)
Source: NeLM - Urology - October 22, 2009 Category: Urology & Nephrology Source Type: organizations

Studies show Viagra, other drugs outperform hormone treatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The so-called PDE5 inhibitors are better at treating erectile dysfunction, according to a new guideline from the American College of Physicians. Just in case anyone out there was unconvinced that erectile dysfunction is best treated by popping one of those well-advertised pills, the American College of Physicians has officially proclaimed the superiority of drugs such as Viagra, Levitra and Cialis over hormone treatment. (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - October 21, 2009 Category: Science Source Type: news

A new approach to the treatment of cerebral vasospasm: the angiographic effects of tadalafil on experimental vasospasmEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Our study results showed that tadalafil has a vasodilatory effect on both acute and chronic periods of cerebral vasospasm. We also concluded that cerebral angiography can be used safely for investigation of cerebral vasospasm in animal studies. Content Type Journal ArticleCategory Experimental ResearchDOI 10.1007/s00701-009-0540-xAuthors Ender Koktekir, Ministry of Health Ankara Education and Research Hospital Neurosurgery Department Ankara TurkeyYavuz Erdem, Ministry of Health Ankara Education and Research Hospital Neurosurgery Department Ankara TurkeyMehmet Akif Bayar, Ministry of Health A...
Source: Acta Neurochirurgica - October 21, 2009 Category: Neurology Tags: Acta Neurochirurgica Source Type: journals

Sexual Satisfaction in Men with Erectile Dysfunction: Correlates and Potential PredictorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Introduction. Sexual satisfaction is an important treatment objective for men with erectile dysfunction (ED).Aims. To evaluate potential associations between International Index of Erectile Function (IIEF) satisfaction at study endpoint and a range of baseline, on-treatment, and endpoint variables.Methods. An exploratory analysis was conducted involving 3,935 subjects with ED randomized to on-demand tadalafil (N = 2,824) or placebo (N = 1,111) in randomized, controlled trials across 28 countries. Patients achieving scores [ge]16 on IIEF questions 7, 8, 13, and 14 at study endpoint were operationally defined as satisfied (v...
Source: The Journal of Sexual Medicine - October 20, 2009 Category: Sexual Medicine Authors: Stanley E. Althof, Jacques Buvat, Stephen W. Gutkin, Mark Belger, Diane R. Stothard, Axel R. Fugl-Meyer Source Type: journals

When Viagra fails: Study looking at stents to help with erectile dysfunctionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Medtronic Inc. is conducting a small study to see if using a stent to prop open arteries near the penis can help men with erectile dysfunction for whom drugs such as Pfizer Inc.'s Viagra and Eli Lilly & Co.'s Cialis don't work. The one-year study will... (Source: OrlandoSentinel: Medical Research)
Source: OrlandoSentinel: Medical Research - October 19, 2009 Category: American Health Source Type: news

Vital Signs: Regimens: Doctors Group Endorses Erectile DrugsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The American College of Physicians cited the lack of bad side effects in offering its support for medications like Viagra. (Source: NYT > Health)
Source: NYT > Health - October 19, 2009 Category: Consumer Health News Authors: By RONI CARYN RABIN Tags: Viagra (Drug) Cialis (Drug) Levitra (Drug) Sex Medicine and Health American College of Physicians Source Type: news

Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Description: The American College of Physicians developed this guideline to present the available evidence on hormonal testing in and pharmacologic management of erectile dysfunction. Current pharmacologic therapies include phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, vardenafil, tadalafil, mirodenafil, and udenafil, and hormonal treatment. Methods: Published literature on this topic was identified by using MEDLINE (1966 to May 2007), EMBASE (1980 to week 22 of 2007), Cochrane Central Register of Controlled Trials (second quarter of 2007), PsycINFO (1985 to June 2007), AMED (1985 to June 2007), and SCOP...
Source: Annals of Internal Medicine - October 18, 2009 Category: Internal Medicine Authors: Qaseem A, Snow V, Denberg TD, Casey DE, Forciea MA, Owens DK, Shekelle P, Tags: Ann Intern Med Source Type: journals

Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Oral PDE-5 inhibitors improved erectile functioning and had similar efficacy and safety profiles. Results on the efficacy of hormonal treatments and the value of hormone testing in men with ED were inconclusive. Primary Funding Source: Agency for Healthcare Research and Quality. PMID: 19843531 [PubMed - as supplied by publisher] (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - October 18, 2009 Category: Internal Medicine Authors: Tsertsvadze A, Fink HA, Yazdi F, Macdonald R, Bella AJ, Ansari MT, Garritty C, Soares-Weiser K, Daniel R, Sampson M, Fox S, Moher D, Wilt TJ Tags: Ann Intern Med Source Type: journals

Effects of 12-Month Tadalafil Therapy for Erectile Dysfunction on Couple Relationships: Results from the DETECT StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions. Improvement of ED with tadalafil was associated with reduced relationship problems, suggesting that problems were associated with ED and resolved with treatment. Verheyden B, Roumeguère T, Bitton A, Belger M, and Schmitt H. Effects of 12-month tadalafil therapy for erectile dysfunction on couple relationships: Results from the DETECT study. J Sex Med **;**:**[ndash]**. (Source: The Journal of Sexual Medicine)
Source: The Journal of Sexual Medicine - October 13, 2009 Category: Sexual Medicine Authors: Benny Verheyden, Thierry Roumeguère, Alain Bitton, Mark Belger, Henry Schmitt Source Type: journals

Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Two closely related series of novel beta-carboline derivatives, electronically similar to tadalafil (CAS 171596-29-5), were synthesized and evaluated for their inhibitory effects upon phosphodiesterase 5 (PDE5) and phosphodiesterase 11 (PDE11) and their in vitro tumor cell growth inhibitory activity versus HT29 colorectal carcinoma cell line. Interestingly, some of the synthesized compounds showed growth inhibitory properties that appear to be associated with their ability to inhibit PDE5. Moreover, the PDE5 inhibition seems relevant to the stereochemical aspects of the compounds. PMID: 19813465 [PubMed - in proces...
Source: Arzneimittel-Forschung - October 11, 2009 Category: Drugs & Pharmacology Authors: Abadi AH, Abouel-Ella DA, Ahmed NS, Gary BD, Thaiparambil JT, Tinsley HN, Keeton AB, Piazza GA Tags: Arzneimittelforschung Source Type: journals

Sildenafil/tadalafil: Sudden sensorineural hearing loss: 2 case reportsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 6, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Gender differences in tail-skin flushing induced by nitrates and phosphodiesterase type 5 inhibitors in a climacteric mouse model.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Flushing is one of the most common vasodilation-related adverse effects associated with both nitrates and phosphodiesterase type 5 (PDE5) inhibitors. The present study aimed to investigate the effects of orchidectomy and ovariectomy on isosorbide dinitrate-, sildenafil-, vardenafil- and tadalafil-induced flushing of tail-skin in mice. Both orchidectomy and ovariectomy markedly increased the tail-skin temperature, a good parameter of flushing, induced by isosorbide dinitrate (500mug/kg, i.p.). These observations suggest that both testosterone withdrawal and estrogen withdrawal are risk factors for isosorbide dinitrate-i...
Source: European Journal of Pharmacology - October 5, 2009 Category: Drugs & Pharmacology Authors: Sejima H, Tominaga K, Egawa T, Ikeda M, Shibuya K, Kameyama N, Yamauchi A, Shuto H, Kataoka Y Tags: Eur J Pharmacol Source Type: journals

Daily Patterns of Sexual Intercourse Attempts by Men With Erectile Dysfunction Treated With Tadalafil: Influence of Age and Marital StatusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
How do the variables of age and marital status influence the effectiveness of tadalafil for erectile dysfunction? International Journal of Impotence Research (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - September 25, 2009 Category: Urology & Nephrology Tags: Urology Source Type: info

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pulmonary arterial hypertension (PAH) is a rare disease characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary arterial resistance, right heart failure, and death. The pathogenesis of PAH is multifactorial, with endothelial cell dysfunction playing an integral role. This endothelial dysfunction is characterized by an overproduction of vasoconstrictors and proliferative factors, such as endothelin-1, and a reduction of vasodilators and antiproliferative factors, such prostacyclin and nitric oxide. Phosphodiesterase type 5 (PDE-5) is implicated in this process by inactiva...
Source: Advances in Therapy - September 18, 2009 Category: Drugs & Pharmacology Authors: Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O Tags: Adv Ther Source Type: journals

Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily ...Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Maimonides Medical Center and Columbia University, New York, NY, USA. (Source: UroToday)
Source: UroToday - September 17, 2009 Category: Urology & Nephrology Tags: Browse Categories - Erectile Dysfunction (ED) Source Type: info

Nanoparticles as a Novel Delivery Vehicle for Therapeutics Targeting Erectile DysfunctionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions. Nanoparticles encapsulating three different erectogenic agents resulted in increased erectile function when applied to the penis of a rat model of ED. Nanoparticles represent a potential novel route for topical delivery of erectogenic agents which could improve the safety profile for existing orally administered drugs by avoiding effects of absorption and first-pass metabolism, and would be less hazardous than injection. Han G, Tar M, Kuppam DSR, Friedman A, Melman A, Friedman J, and Davies KP. Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction. J Sex Med **;**:**[ndash]*...
Source: The Journal of Sexual Medicine - September 17, 2009 Category: Sexual Medicine Authors: George Han, Moses Tar, Dwaraka S. R. Kuppam, Adam Friedman, Arnold Melman, Joel Friedman, Kelvin P. Davies Source Type: journals

Topical Erectile Dysfunction Therapy Shows PromiseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study was done to evaluate whether the Einstein nanoparticles, which have been shown to penetrate the skin, might allow the targeted delivery of compounds that treat ED and thereby avoid the drugs’ systemic effects. An effective topical therapy could be especially significant for those ED patients – particularly men with diabetes – who have reduced levels of nitric oxide (NO), the signaling molecule that dilates blood vessels responsible for erectile activity. These men, who often aren’t helped by oral PDE5 inhibitor drugs, may benefit from direct application of NO or the PDE5 inhibitors. The nanoparticles w...
Source: Diabetes News from dLife.com - September 16, 2009 Category: Consumer Health News Authors: dlife Source Type: info

Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Tadalafil appears to be safe and well tolerated but lacks efficacy in comparison to placebo as a treatment for RP secondary to SSc. PMID: 19755613 [PubMed - as supplied by publisher] (Source: J Rheumatol)
Source: J Rheumatol - September 14, 2009 Category: Rheumatology Authors: Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR Tags: J Rheumatol Source Type: journals

[Chronic PDE-5 inhibition in patients with erectile dysfunction : New treatment approach using once daily Tadalafil.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Erectile dysfunction (ED) is often associated with increased cardiovascular risk. There is increasing evidence suggesting that dysfunction of the vascular endothelium with reduced bioavailability of nitric oxide (NO) may be the pathogenetic link between ED and cardiovascular disease. The crucial importance of the NO-guanylatecyclase-cGMP-phosphodiesterase pathway for penile erection is mirrored by the efficacy of phosphodiesterase-5 (PDE5) inhibitors in the treatment of ED. In contrast to other currently available PDE5 inhibitors with a half-life time of about 4 h Tadalafil has a half-life time of about 17.5 h resultin...
Source: Der Urologe. Ausg. A - September 8, 2009 Category: Urology & Nephrology Authors: Porst H, Hell-Momeni K, Büttner H Tags: Urologe A Source Type: journals

Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To determine, by post hoc analysis, the effects of tadalafil (a long-acting phosphodiesterase 5 inhibitor) on peak urinary flow (Qmax), bladder capacity, voiding efficiency and the obstructive symptoms of benign prostatic hyperplasia (BPH) in men with lower urinary tract symptoms secondary to BPH (BPH-LUTS), compared with placebo. After a 4-week placebo run-in period, 1058 men with BPH-LUTS were randomly allocated to receive once daily treatment with placebo or tadalafil (2.5, 5, 10, or 20 mg) for 12 weeks. Uroflowmetry, postvoid residual volume (PVR), and BPH symptom score measurements were assessed throughout the trial. ...
Source: BJU International - September 2, 2009 Category: Urology & Nephrology Authors: Claus G. Roehrborn, Jed C. Kaminetsky, Stephen M. Auerbach, Rafael Martínez Montelongo, Albert Elion-Mboussa, Lars Viktrup Source Type: journals

Nerve-Sparing Radical Retropubic Prostatectomy: What Are The Expectations of Potency Preservation in the PDE5 Era?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: The purpose of the study was to evaluate potency following Radical Retropubic Prostatectomy (RRP), in the era of phosphodiesterase (PDE5) inhibitors. Methods: 100 consecutive patients who underwent nerve sparing RRP and were potent preoperatively were analyzed postoperatively for the preservation of erectile function. All operations were performed by the same surgeon using the Walsh technique. The determination of which side to spare, and which to resect, was based on preoperative parameters as well as intraoperative findings. The clinical staging was: cT1=42%, cT2=49% & cT3=9%. Bilateral nerve sparing was per...
Source: Journal of Men's Health - August 31, 2009 Category: Primary Care Authors: R. Khauli, A. Kharrouby, B. Bachir, O. Darwish Tags: WCMH Abstracts Source Type: journals

Comparing the three PDE-5 inhibitors in the same populationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Objective: This independent prospective, cross-over, observational and open-label study was undertaken to assess both efficacy, patients’ preference and side-effect profile of Sildenafil, Tadalafil and Vardenafil in the same population. (Source: Journal of Men's Health)
Source: Journal of Men's Health - August 31, 2009 Category: Primary Care Authors: A. Yassin, F. Saad Tags: WCMH Abstracts Source Type: journals

Patient Money: For Common Male Problem, Hope Beyond a PillEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
For some, pills like Viagra and Cialis don’t work. And even if they do, there are more cost-effective ways to treat a problem that grows more common with age. (Source: NYT > Health)
Source: NYT > Health - August 29, 2009 Category: Consumer Health News Authors: By LESLEY ALDERMAN Tags: Viagra (Drug) Penis Medical Devices Sex Medicine and Health Drugs (Pharmaceuticals) Source Type: news

Penile rehabilitation protocol after robot-assisted radical prostatectomy: assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potencyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To evaluate factors that affect compliance in men who enrol in a phosphodiesterase type 5 inhibitor (PDE5I) protocol after nerve-sparing robot-assisted prostatectomy (RAP), and report on short-term outcomes, as PDE5Is may help restore erectile function after RAP and patient adherence to the regimen is a factor that potentially can affect outcome. We prospectively followed 77 men who had nerve-sparing RAP and enrolled in a postoperative penile rehabilitation protocol. The men received either sildenafil citrate or tadalafil three times weekly. The minimum follow-up was 8 weeks. Potency was defined as erection adequate for pe...
Source: BJU International - August 27, 2009 Category: Urology & Nephrology Authors: Daniel J. Lee, Philippa Cheetham, Ketan K. Badani Source Type: journals

Steam Dietary SupplementEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Audience: Consumers, pharmacists [UPDATED 08/24/2009] Nutracoastal has found by lab analysis that Lot 90260 contains Tadalafil, an active ingredient of an FDA-approved drug for erectile dysfunction, making Steam an unapproved drug. The lot number... (Source: Drugs.com - FDA MedWatch Alerts)
Source: Drugs.com - FDA MedWatch Alerts - August 24, 2009 Category: Drugs & Pharmacology Source Type: news

Link Between Erectile Dysfunction And Obesity Explored in Obesity and Weight ManagementEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
August 24, 2009 (EurekAlert) - Obese men are at increased risk for erectile dysfunction (ED), likely caused by atherosclerosis-related hypertension and cardiovascular disease, as well as hormonal changes associated with obesity, as described in a timely article published in Obesity and Weight Management, a journalzine published by Mary Ann Liebert, Incorporated. As many as 30-40% of men over the age of 50 may experience ED, and both obesity and physical inactivity may increase their risk. The build-up of atherosclerotic plaque in the arteries of obese men can damage the arterial lining and contribute to elevated blood ...
Source: Diabetes News from dLife.com - August 23, 2009 Category: Consumer Health News Authors: dlife Source Type: info

Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion sildenafil, vardenafil and tadalafil show similar efficacy in the clinical practice. However, patients receiving tadalafil display a lower risk to discontinue or change the treatment.Asian Journal of Andrology advance online publication. 24 Augest 2009; doi: 10.1038/aja.2009.48. PMID: 19701217 [PubMed - as supplied by publisher] (Source: Asian Journal of Andrology)
Source: Asian Journal of Andrology - August 23, 2009 Category: Urology & Nephrology Authors: Fusco F, Sicuteri R, Rossi A, Kontodimas S, Haro JM, Imbimbo C, Tags: Asian J Androl Source Type: journals

Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitroEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: We have shown that curcumin acts on localized prostate cancer to induce apoptosis and may therefore be an option as a future therapeutic agent. (Source: International Braz J Urol)
Source: International Braz J Urol - August 22, 2009 Category: Urology & Nephrology Source Type: journals

Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced USEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions In patients with BPH, vascular changes are observed in the prostate after Tadalafil administration, which can be detected with CEUS. Content Type Journal ArticleCategory Uro-Genital Radiology/Radiologia Uro-GenitaleDOI 10.1007/s11547-009-0449-8Authors M. Bertolotto, Università di Trieste, Ospedale di Cattinara UCO di Radiologia Strada di Fiume 449 34149 Trieste ItalyE. Trincia, Università di Trieste, Ospedale di Cattinara UCO di Radiologia Strada di Fiume 449 34149 Trieste ItalyR. Zappetti, Università di Trieste, Ospedale di Cattinara UCO di Radiologia Strada di Fiume 449 34149 Trieste I...
Source: La Radiologia Medica - August 20, 2009 Category: Radiology Tags: La Radiologia Medica Source Type: journals

PDE-5 Inhibitors May Be Useful for Benign Prostatic HyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The biologic effects of phosphodiesterase-5 inhibitors (PDE5-Is), such as sildenafil and tadalafil, may make them useful agents for treating lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH), Belgian researchers report in the August issue of BJU International. However, much research remains to be done. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 13, 2009 Category: Consumer Health News Tags: Urology Source Type: news

CIALIS (Tadalafil) Tablet, Film Coated [Eli Lilly And Company]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Aug 13, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 13, 2009 Category: Drugs & Pharmacology Source Type: organizations

Phosphodiesterase Type 5 Inhibitors Facilitate Noncontact Erections in Male Rats: Site of Action in the Brain and Mechanism of ActionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions. The results suggest that PDE5i may increase sexual arousal by acting in the central nervous system. This effect may be mediated (at least in part) by the activation of mesolimbic dopaminergic neurons. Sanna F, Succu S, Boi A, Melis MR, and Argiolas A. Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: Site of action in the brain and mechanism of action. J Sex Med **;**:**[ndash]**. (Source: The Journal of Sexual Medicine)
Source: The Journal of Sexual Medicine - August 11, 2009 Category: Sexual Medicine Authors: Fabrizio Sanna, Salvatora Succu, Antonio Boi, Maria Rosaria Melis, Antonio Argiolas Source Type: journals

Timing of Dose Relative to Sexual Intercourse Attempt in Previous Sildenafil Citrate Users Treated with Tadalafil: A Geographical Comparison from a Single Arm, Open-Label StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion. Men with a history of established sildenafil citrate use alter their dose-attempt behavior when treated with tadalafil irrespective of geography. However, the extent to which sexual behavior alters is not uniform across geographical regions, suggesting that dosing instructions and duration of drug effectiveness, in combination with personal and cultural preferences, may determine sexual behavior with PDE5 inhibitor use. Rubio-Aurioles E, Glina S, Abdo CHN, Hernandez-Serrano R, Rampazzo C, Sotomayor M, West TM, Gallagher GL, and Lenero E. Timing of dose relative to sexual intercourse attempt in previous sildenaf...
Source: The Journal of Sexual Medicine - August 10, 2009 Category: Sexual Medicine Authors: Eusebio Rubio-Aurioles, Sidney Glina, Carmita H.N. Abdo, Ruben Hernandez-Serrano, Claudia Rampazzo, Mariano Sotomayor, Teena M. West, Gabrielle L. Gallagher, Enrique Lenero Source Type: journals

Effect of Tadalafil on Renal Resistivity and Pulsatility Index in Partial Ureteral ObstructionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Urol Int 2009;83:75-79 (DOI:10.1159/000224873) (Source: Karger Publishers)
Source: Karger Publishers - July 27, 2009 Category: Cancer & Oncology Source Type: journals

The application of quantitative methods for identifying and exploring the presence of bias in systematic reviews: PDE-5 inhibitors for erectile dysfunctionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: DARE Area: Evidence > Drug Class Focused Reviews CRD Summary: This review of the efficacy of sildenafil, tadalafil and vardenafil for the treatment of erectile dysfunction concluded that all three drugs are highly effective; no differences were identified between them. The authors thoroughly investigated possible sources of bias in the review; their conclusions were in line with the evidence presented and likely to be reliable. CRD Commentary: This review had clear inclusion criteria for participants, interventions and study designs. Inclusion criteria for outcomes were broad, but this appeared unlikely to have ...
Source: NeLM - Drug Class Focused Reviews - July 16, 2009 Category: Drugs & Pharmacology Source Type: organizations

Nature & Health Co. Issues Voluntary Nationwide Recall of Six Male Enhancement Products Marketed as Dietary SupplementsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Opteron 1 Inc. dba Nature & Health Co., announced today that it is conducting a voluntary nationwide recall of the company's five supplement products sold under the following names: LibieXtreme, Y-4ever, Libimax X Liquid, Powermania Liquid and Capsule, Herbal Disiac. The Company has been informed by representatives of the Food and Drug Administration (FDA) that lab analysis by FDA of these five samples found they contains either tadalafil, an active ingredient of an FDA-approved drug for erectile dysfunction (ED) , its analog aminotadalafil, or the analog of sidenafil, an active ingredient of another FDA-approved ED drug, ...
Source: Food and Drug Administration - July 15, 2009 Category: Food Science Source Type: organizations

Effects Of Once-Daily Tadalafil On Erectile Function In Men With Erectile Dysfunction And Signs And Symptoms Of Benign Prostatic HyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
UroToday.com - Men with benign prostatic hyperplasia (BPH) often suffer from lower urinary tract symptoms (LUTS; BPH-LUTS) such as urinary frequency, urgency, intermittency, nocturia, straining, incomplete emptying, or weak urinary stream. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2009 Category: Consumer Health News Tags: Erectile Dysfunction / Premature Ejaculation Source Type: news